- Home
- IMCR vs FSM Comparison
IMCR vs FSM Comparison
Compare IMCR & FSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | FSM |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United Kingdom | Canada |
| Employees | 493 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.9B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMCR | FSM |
|---|---|---|
| Price | $36.13 | $10.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $67.00 | $11.00 |
| AVG Volume (30 Days) | 259.5K | ★ 6.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 809.52 |
| EPS | N/A | ★ 0.74 |
| Revenue | $379,590,000.00 | ★ $1,256,829,000.00 |
| Revenue This Year | $32.28 | $0.28 |
| Revenue Next Year | $10.66 | $11.27 |
| P/E Ratio | ★ N/A | $13.44 |
| Revenue Growth | 28.11 | ★ 68.17 |
| 52 Week Low | $23.15 | $4.13 |
| 52 Week High | $40.72 | $10.38 |
Technical Indicators
Market Signals| Indicator | IMCR | FSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 66.95 |
| Support Level | $35.41 | $9.85 |
| Resistance Level | $37.25 | $10.34 |
| Average True Range (ATR) | 1.58 | 0.40 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 20.63 | 92.98 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.